Table 1.

Description of FDA-approved antiviral drugs. GFR: glomerular filtration rate.

Antiviral	Indications and Dosage	Interactions with Other Drugs	Effectiveness	References
Molnupiravir (Lagevrio)	Outpatient treatment of mild to moderate COVID-19 in adults (≥18 years). Initiate as soon as possible and within 5 days of symptom onset.	No drug interactions with molnupiravir have yet been identified.	Antiviral activity against SARS-CoV-2 in cell culture assays with a 50% effective concentration (EC50) ranging between 0.67 to 2.66 µM. NHC had similar activity against the variants including Alpha, Beta, Gamma, and Delta.	[23,25,26]
	Oral use: 200 mg capsules. The authorized dose is 800 mg every 12 h for 5 days.
	Not recommended in severe renal impairment (eGFR < 30 mL/min).
Nirmatrelvir-Ritonavir (Paxlovid)	Outpatient treatment of mild to moderate COVID-19 in adults and in children down to age 12 who weigh at least 40 kg. Initiate as soon as possible and within 5 days of symptom onset.	Of major concern, altered drug concentrations are contraindicated due to possible serious or life-threatening reactions.	Antiviral activity against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Lambda variants. Activity against SARS-CoV2 in A549-ACE2 cells is of 77.9 and a 90% effective concentration (EC90) of 215 nM.	[23,27]
	Oral use: 150 mg nirmatrelvir and 100 mg ritonavir.
	The authorized dose is 300–100 mg every 12 h for 5 days